anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The 4-n-butylresorcinol emulsion or nanopowder having anti-inflammatory, anti-oxidative and skin-whitening effects is provided to reduce skin irritation and improve stability against oxygen of 4-n-butylresorcinol by dissolving it in gamma linolenic acid and powdering with amino acids. The 4-n-butylresorcinol emulsion comprises 10-20 wt.% of 4-n-butylresorcinol, 5-15 wt.% of gamma linolenic acid, 1-3 wt.% of emulsifier such as lecithin or fatty acid ester and 20-50 wt.% of amino acid. A method for preparing the 4-n-butylresorcinol emulsion comprises the steps of: dissolving amino acids in distilled water; adding gamma linolenic acid into the amino acid solution, and stirring the mixture; adding the emulsifier and 4-n-butylresorcinol into the gamma linolenic acid solution and stirring the mixture to form emulsion; and adding oligosaccharide into the emulsion to prepare gamma linolenic acid-amino acid-4-n-butyllinolenic acid emulsion. The 4-n-butylresorcinol nanopowder is prepared by drying the prepared gamma linolenic acid-amino acid-4-n-butyllinolenic acid emulsion through freeze-drying or spray-drying. A cosmetic composition comprises 4-n-butylresorcinol emulsion. Further, the gamma linolenic acid is selected from a group consisting of Borage oil, Oenothera odorata oil and Blackcurrant oil.
Lower urinary tract dysfunction, such as incontinence or urinary retention, is one of the leading consequences of neurological diseases. This significantly impacts the quality of life for those affected, with implications extending not only to humans but also to clinical veterinary care. Having motor and sensory fibers, the pudendal nerve is an optimal candidate for neuromodulation therapies using bidirectional intraneural prostheses, paving the way towards the restoration of a more physiological urination cycle: bladder state can be detected from recorded neural signals, then an electrical current can be injected to the nerve based on the real-time need of the bladder. To develop such prostheses and investigate this novel approach, animal studies are still required since the morphology of the target nerve is fundamental to optimizing the prosthesis design. This study aims to describe the porcine pudendal nerve as a model for neuromodulation studies aiming at restoring lower urinary tract dysfunction. Five male farm pigs were involved in the study. First, a surgical procedure to access the porcine pudendal nerve without muscle resection was developed. Then, an intraneural interface was implanted to confirm the presence of fibers innervating the external urethral sphincter by measuring its electromyographic activity. Finally, the morphophysiology of the porcine pudendal nerve at the level of surgical exposure was described by using histological and immunohistochemical characterization. This analysis confirmed the fasciculate nature of the nerve and the presence of mixed fibers with a spatial and functional organization. These achievements pave the way for further pudendal neuromodulation studies by using a clinically relevant animal model with the potential for translating the findings into clinical applications.
Background: Dying in nonpalliative acute care is generally considered inappropriate and avoidable. Place of death, a commonly reported big-dot indicator of end-of-life care quality, is often used as a proxy for place of care despite no empirical evidence for their correlations. Thus, we examined the correlations between place of death and place of care in the last month of life. We also investigated anecdotal claims that individuals cared in acute care often get discharged to die at home, and vice versa. Methods: We conducted a retrospective cohort study of Ontario decedents (18+) who died between January 1, 2015 and December 31, 2017. We identified individuals who died in nonpalliative acute care, palliative care unit, subacute care, long-term care (LTC), and the community. We calculated the number of days decedents spent in each setting in their last month of life, and used descriptive analyses to investigate their correlations. Results: Decedent's place of death generally correlated with their place of care in the last month of life-individuals who died in a particular setting spent more time in that setting than individuals who died elsewhere. Furthermore, 75.0% of individuals who spent more than two weeks of their last month in acute care died in acute care. Among individuals who died in the community and in LTC, 65.4% and 75.0%, respectively, spent zero days in acute care. Interpretation: We showed that place of death can be a useful high-level performance indicator, by itself and as a proxy for place of care, to gauge end-of-life quality and service provision/implementation.
Hippocampal sclerosis (HS) refers to neuronal cell loss and astrocytosis in subiculum and cornu ammonis subfields of the hippocampal formation unrelated to Alzheimer's disease pathology. In contrast to HS that affects younger adults with epilepsy, older individuals with HS have significant ante-mortem cognitive dysfunction but no epilepsy. Neuropathological studies demonstrated three main types of HS associated with aging: (a) HS-Ageing to refer to the disease with HS pathology in ageing individuals, observed in more than 10% of subjects aged over 85 years; (b) HS observed in the behavioural variant of frontotemporal dementia (bvFTD), HS being more frequent in tau-negative pathology, especially in FTLD-TDP. bvFTD patients may manifest severe episodic memory impairment and hippocampal atrophy; (c) HS associated with cortical or subcortical cerebral microinfarcts, which are invisible on conventional MRI. Cerebral microinfarcts are observed in 33% of elderly over 85 years in post-mortem studies.

HS leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.
INTRODUCTION: Shoulder dystocia is a rare obstetric complication, and the risk of recurrence is important for planning future deliveries.
MATERIAL AND METHODS: The objectives of our study were to estimate the incidence and risk factors for recurrence of shoulder dystocia and to identify women at high risk of recurrence in a subsequent vaginal delivery. The study design was a nationwide register-based study including data from the Danish Medical Birth Registry and National Patient Register in the period 2007-2017. Nulliparous women with a singleton fetus in cephalic presentation were included for analysis of risk factors in index and subsequent delivery.
RESULTS: During the study period, 6002 cases of shoulder dystocia were reported with an overall incidence among women with vaginal delivery of 1.2%. Among 222 225 nulliparous women with vaginal births, shoulder dystocia complicated 2209 (1.0%) deliveries. A subsequent birth was registered in 1106 (50.1%) of the women with shoulder dystocia in index delivery of which 837 (77.8%) delivered vaginally. Recurrence of shoulder dystocia was reported in 60 (7.2%) with a six-fold increased risk compared with women without a prior history of shoulder dystocia (risk ratio [RR] 5.70, 95% confidence interval [CI]: 4.41 to 7.38; adjusted RR 3.06, 95% CI: 2.03 to 4.68). Low maternal height was a significant risk factor for recurrence of shoulder dystocia. In the subsequent delivery, significant risk factors for recurrence were birthweight >4000 g, positive fetal weight difference exceeding 250 g from index to subsequent delivery, stimulation with oxytocin and operative vaginal delivery. In the subsequent pregnancy following shoulder dystocia, women who underwent a planned cesarean (n = 176) were characterized by more advanced age and a higher prevalence of diabetes in the subsequent pregnancy. Furthermore, they had more often experienced operative vaginal delivery, severe perineal lacerations, and severe neonatal complications at the index delivery.
CONCLUSIONS: The incidence of shoulder dystocia among nulliparous women with vaginal delivery was 1.0% with a 7.2% risk of recurrence in a population where about 50% had a subsequent birth and of these 78% had subsequent vaginal delivery. Important risk factors for recurrence were low maternal height, increase of birthweight ≥250 g from index to subsequent delivery and operative vaginal delivery.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic cancer originating from the malignant transformation of plasmacytoid dendritic cell precursors. This malignancy progresses rapidly, with frequent relapses and a poor overall survival rate, underscoring the urgent need for effective treatments. However, diagnosing and treating BPDCN have historically been challenging due to its rarity and the lack of standardized approaches. The recognition of BPDCN as a distinct disease entity is recent, and standardized treatment protocols are yet to be established. Traditionally, conventional chemotherapy and stem cell transplantation have been the primary methods for treating BPDCN patients. Advances in immunophenotyping and molecular profiling have identified potential therapeutic targets, leading to a shift toward CD123-targeted immunotherapies in both clinical and research settings. Ongoing developments with SL-401, IMGN632, CD123 chimeric antigen receptor (CAR) T-cells, and bispecific antibodies (BsAb) show promising advancements. However, the therapeutic effectiveness of CD123-targeting treatments needs improvement through innovative approaches and combinations of treatments with other anti-leukemic drugs. The exploration of combinations such as CD123-targeted immunotherapies with azacitidine and venetoclax is suggested to enhance antineoplastic responses and improve survival rates in BPDCN patients. In conclusion, this multifaceted approach offers hope for more effective and tailored therapeutic interventions against this challenging hematologic malignancy.
The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
A device for administering elongate medicinal pellets in subcutaneous applications. The device includes a hand-held guide element including a hollow barrel enclosing a sliding member having a needle locking means at one end thereof. A disposable cartridge element includes a hollow needle containing a pellet to be implanted and an obturator of length somewhat greater than that of the needle. In use, the cartridge element is engaged at an end thereof with the guide element. The free end of the needle is inserted into the subcutaneous fat of the patient, and the sliding member is moved in an opposite direction to withdraw the needle into the hollow barrel. During this movement, the obturator is maintained relatively stationary by engaging an abutment on the guide element, at one end thereof, the opposite end of the obturator engaging an end of the pellet, so that as the needle is withdrawn, the pellet remains in implanted position. A composite pellet having a core formed of a first ingredient, and a surrounding sleeve formed of a second ingredient is also disclosed, as is a method for making the pellets using a soluble inert core having first and second ingredients coated thereon.
<P>PROBLEM TO BE SOLVED: To provide a fermented food useful for maintaining health, preventing various diseases and enhancing the effect for treating the diseases at a low cost, and to provide an intestinal useful bacterial substance at a low cost.  <P>SOLUTION: This fermented food is obtained by fermenting an intestinal useful bacterium having non-transmissional resistance against antibiotics in a culture medium. The intestinal useful bacterium sometimes has multiple resistance against antibiotics. The fermented food sometimes contains a proliferation- promoting substance for the intestinal useful bacterium. The culture medium is a milk culture medium or a soybean milk culture medium. The intestinal useful bacterial substance comprises the intestinal useful bacterium having non-transmissional resistance against antibiotics and the proliferation-promoting substance for the intestinal useful bacterium.  <P>COPYRIGHT: (C)2003,JPO
1,142,649. Microcapsules. WALLACE & TIERNAN Inc. 31 March, 1966 [31 March, 1965], No. 14279/66. Heading B8C. [Also in Division C3] The process set out in Specification 1,091,141 is modified where the capsule skin forms by growing outwards from the encapsulated liquid into the continuous phase liquid, by addition of a solid colloidal dispersion agent at least to the continuous phase liquid. This forms on the capsules a coating which reduces agglomeration. The encapsulated liquid is generally hydrophilic and the continuous phase liquid organic. Examples of dispersing agents are colloidal magnesium aluminium silicate, activated attapulgite, talc and rice powder starch.
<P>PROBLEM TO BE SOLVED: To obtain a new allergen protein associated with mite allergic diseases except Der f or Der p family, a diagnostic, a prophylactic, a therapeutic agent, etc., using the same.  <P>SOLUTION: The protein is contained in an extract of mite polypide, exhibits a molecular weight of about 15kDa measured by an SDS-polyacrylamide gel electrophoresis method and an isoelectric point in the vicinity of about 5.5 measured by an isoelectric point electrophoresis method and has characteristics of exhibiting a cross-reaction with IgE. The new allergen protein exhibits homology to the mite allergen of group 2 by analyzing the protein by ESI Q-TOF MS. Thereby, the new mite allergen protein is obtained. The polynucleotide encoding the protein is obtained, and the antibody recognizing the protein is obtained. The diagnostic, the prophylactic, the therapeutic agent of mite allergic diseases, etc., are obtained by using the same.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Glucocorticoids are the first-line antiinflammatory treatment for asthma. Their multiple inhibitory properties, including the inhibition of Th2 cytokine synthesis, are likely to contribute to clinical efficacy. Glucocorticoids also enhance IL-10 production in vitro by human CD4+ and CD8+ T cells, and glucocorticoid treatment induces the synthesis of IL-10 by airway cells in asthmatic patients. IL-10 is a potent antiinflammatory and immunosuppressive leading to profound inhibition of Th1 cell-mediated immunity. A proportion of asthmatic patients fails to benefit from oral glucocorticoid therapy and are thus denoted as having glucocorticoid-resistant (SR, derived from "steroid resistant") or insensitive asthma. It has been demonstrated that CD4+ T cells from SR asthma patients fail to induce IL-10 synthesis following in vitro stimulation in the presence of dexamethasone as compared with their glucocorticoid-sensitive counterparts (SS, derived from "steroid sensitive"), suggesting a link between induction of IL-10 synthesis and clinical efficacy of glucocorticoids. One potential source of IL-10 is Tregs, which control the function of effector T cells. Glucocorticoids enhance the production of IL-10 by polyclonally stimulated T cells and these cells inhibit IFN- production by human CD4+ T cells in an IL-10-dependent manner. In both mouse and human a combination of dexamethasone and calcitriol, the active form of vitamin D3, induced high numbers of IL-10-producing T cells that made negligible amounts of Th1 and Th2 cytokines.

Xystrakis et al. (57) showed that IL-10-secreting Tregs inhibit cytokine production by previously activated allergen-specific Th2 cells and that pretreating T cells with IL-10 or adding vitamin D3 to the cell cultures can reverse the defect and enhance IL-10 production by Tregs from asthmatic patients who were resistant to glucocorticoid therapy. These manipulations increase IL-10 production to levels comparable to those observed in patients who do respond well to therapy. IL-10 increases glucocorticoid receptor expression, and the authors proposed that this is the mechanism by which IL-10 overcomes the glucocorticoid-resistant patient defect in IL-10 synthesis. This strongly suggests that vitamin D3 could potentially increase the therapeutic response to glucocorticoids in SR patients.

We want to test the hypothesis, that vitamin D3 improves pulmonary function and quality of life in patients with asthma relatively resistant to glucocorticoids.
Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
The invention relates to a pillow with a hypnotic effect, which is made from Chinese herbal medicines. The pillow is characterized by comprising a pillow outer cover (1), a sponge layer (2) with the thickness of 0.5-1cm, a pillow inner cover (3) and evenly mixed medicines (4) packed by the pillow inner cover from the outside to inside. The evenly mixed medicines (4) are composed of the following bulk pharmaceutical chemicals according to weight (dry substances): 150-350 grams of radix angelicae pubescentis, 50-130 grams of flos albiziae, 50-150 grams of Mount man myrcia, 80-150 grams of artemisia annua and 1200-1800 grams of Chinese pine saw dust. The pillow provided by the invention has the functions of calming nervousness, promoting hypnosis, soothing the nerves, relieving depression, activating collaterals, stimulating the menstrual flow and eliminating causes for insomnia and amnesia. The pillow can not only improve the quality of sleep and serve as a pillow. In addition, the pillow integrates life nourishment with disease treatment by both treating diseases and strengthening physical health.
BACKGROUND: Immunoglobulin A vasculitis (IgAV) is a kind of systemic vasculitis mediated by IgA immune complexes (IgA-ICs). Soluble CD89-IgA complex (sCD89-IgA) as a type of IgA-IC associated with renal involvement in IgAV, the ability of blood sCD89-IgA as a biomarker to predict renal or multi-organ involvement in children with IgAV is not evident, and this study mainly focused on this.
METHODS: The clinical characteristics and blood samples of 57 pediatric patients with IgAV were collected. ELISA was used to detect plasma IgA-ICs and sCD89-IgA levels. Serum IgA levels were detected by Nephelometry method. Statistical analysis was conducted to analyze the relationship between sex, age, serum IgA levels, plasma IgA-ICs levels, plasma sCD89-IgA levels and the involvement of multiple organs (except skin) including kidneys in these patients.
RESULTS: Compared to patients with simple skin involvement, patients with multi-organ involvement, especially kidneys, had higher levels of plasma IgA-ICs and sCD89-IgA, and the statistical difference was significant. In addition, a high level of plasma sCD89-IgA was a high-risk factor for patients to develop multi-organ or renal involvement in addition to the skin. ROC curve analysis showed that the AUC was 0.861 (Sensitivity: 83 %, Specificity: 88 %, p < 0.0001) when plasma sCD89-IgA predicted multi-organ involvement, and AUC 0.926 (Sensitivity: 94 %, Specificity: 88 %, p < 0.0001) for predicting renal involvement.
CONCLUSIONS: The results suggested that plasma sCD89-IgA may be a potential biomarker for predicting multi-organ involvement (in addition to skin), especially renal involvement in IgAV pediatric patients.
Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney-protective effect of the GLP-1RA class of medications has been derived from kidney-related outcomes reported from cardiovascular outcome trials (CVOTs). GLP-1RAs have been shown to reduce albuminuria, mitigate cardiovascular risk, and possibly attenuate estimated glomerular filtration rate (eGFR) decline. The kidney-protective effects of GLP-1RAs are thought to be attributed to their anti-inflammatory, antioxidant, and vasodilatory properties. Despite these promising findings, the use of GLP-RAs has yet to be definitively shown to slow progression to chronic kidney failure in people with T2DM. The Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW trial) is the first major trial assessing the potential of a GLP-1RA to slow progression of kidney disease in people with established CKD to clinically important kidney end points. On March 5, 2024, the top line result from FLOW was announced with semaglutide 1.0 mg being reported to reduce the primary end point of the trial by a significant 24% compared with placebo. Here, we summarize the kidney outcomes reported from CVOTs for the GLP-1RA class of medication and briefly describe kidney outcomes from other major GLP-1RAs trials. We also discuss a potential role of the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, as a kidney-protective agent.